Skip to main content
SpringerLink
Log in

Monitoring Treatment: Clinical and Programmatic Approach for Drug-Susceptible and Drug-Resistant Tuberculosis

  • Chapter
  • First Online:
Essential Tuberculosis

  • 1233 Accesses

Abstract

Tuberculosis (TB) treatment management of patients becomes more difficult with increasing drug resistance. Monitoring of TB treatment is therefore of utmost importance to increase the success rate and prevent complications. This chapter provides an overview of the most critical microbiological, clinical and drug-related parameters at the start and during the treatment of tuberculosis. Therapeutic drug monitoring has been recommended in order to further minimize drug-related adverse reactions and optimize treatment response. An approach on how to include personalized management in programmatic treatment is included.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. World Health Organization (WHO). Global TB report. Geneva: WHO; 2019.

    Google Scholar 

  2. World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: WHO; 2019. https://apps.who.int/iris/bitstream/handle/10665/311389/9789241550529-eng.pdf?ua=1.

    Google Scholar 

  3. Nahid P, Mase SR, Migliori GB, et al. Treatment of drug-resistant tuberculosis an official ATS/CDC/ERS/IDSA clinical practice guideline. Am J Respir Crit Care Med. 2019;200(10):E93–142.

    Article  Google Scholar 

  4. Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2017;63(7):e147–95.

    Article  Google Scholar 

  5. World Health Organization (WHO) Regional Office for Europe. Algorithm for laboratory diagnosis and treatment-monitoring of pulmonary tuberculosis and drug-resistant tuberculosis using state-of-the-art rapid molecular diagnostic technologies. Geneva: WHO; 2017. http://www.euro.who.int/__data/assets/pdf_file/0006/333960/ELI-Algorithm.pdf

    Google Scholar 

  6. World Health Organization (WHO). Definitions and reporting framework for tuberculosis – 2013 revision. Geneva: WHO; 2020. https://www.who.int/tb/publications/definitions/en/

  7. Piubello A, Souleymane MB, Hassane-Harouna S, et al. Management of multidrug-resistant tuberculosis with shorter treatment regimen in Niger: nationwide programmatic achievements. Respir Med. 2020;161:105844.

    Article  Google Scholar 

  8. Migliori GB. Evolution of programmatic definitions used intuberculosis prevention and care. Clin Infect Dis. 2019;68(10):1787–9.

    Article  CAS  Google Scholar 

  9. Nicol MP. Xpert MTB/RIF: monitoring response to tuberculosis treatment. Lancet Respir Med. 2013;1(6):427–8.

    Article  Google Scholar 

  10. Borisov S, Danila E, Maryandyshev A, et al. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report. Eur Respir J. 2019;54(6):1901522.

    Article  Google Scholar 

  11. Alffenaar J-WC, Gumbo T, Dooley KE, et al. Integrating pharmacokinetics and pharmacodynamics in operational research to end TB. Clin Infect Dis. 2019;2019:pii: ciz942.

    Google Scholar 

  12. Van Der Burgt EPM, Sturkenboom MGG, Bolhuis MS, et al. End TB with precision treatment! Eur Respir J. 2016;47(2):680–2.

    Article  Google Scholar 

  13. Vu DH, Alffenaar JWC, Edelbroek PM, Brouwers JRBJ, DR a U. Dried blood spots: a new tool for tuberculosis treatment optimization. Curr Pharm Des. 2011;17(27):2931–9.

    Article  CAS  Google Scholar 

  14. Migliori GB, Tiberi S, Zumla A, et al. MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. Int J Infect Dis. 2020;92S:S15–25.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculty of Medicine and Health, School of Pharmacy, University of Sydney, Sydney, NSW, Australia

    Jan-Willem C. Alffenaar & Hannah Yejin Kim

  2. Westmead Hospital, Sydney, NSW, Australia

    Jan-Willem C. Alffenaar & Hannah Yejin Kim

  3. Marie Bashir Institute for Infectious Diseases and Biosecurity, University of Sydney, Sydney, NSW, Australia

    Jan-Willem C. Alffenaar

  4. University of New South Wales, Kensington, NSW, Australia

    Anthony Byrne

  5. St Vincent’s Hospital Clinical School, Sydney, NSW, Australia

    Anthony Byrne

  6. Damien Foundation, Niamey, Nigeria

    Alberto Piubello

  7. Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri, IRCCS, Tradate, Italy

    Giovanni Battista Migliori

  8. Blizard Institute, Queen Mary University of London, London, UK

    Giovanni Battista Migliori

Authors
  1. Jan-Willem C. Alffenaar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hannah Yejin Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anthony Byrne
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alberto Piubello
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Giovanni Battista Migliori
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jan-Willem C. Alffenaar .

Editor information

Editors and Affiliations

  1. Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Italy

    Giovanni Battista Migliori

  2. Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milan, Italy

    Mario C. Raviglione

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Alffenaar, JW.C., Kim, H.Y., Byrne, A., Piubello, A., Migliori, G.B. (2021). Monitoring Treatment: Clinical and Programmatic Approach for Drug-Susceptible and Drug-Resistant Tuberculosis. In: Migliori, G.B., Raviglione, M.C. (eds) Essential Tuberculosis. Springer, Cham. https://doi.org/10.1007/978-3-030-66703-0_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-66703-0_18

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-66705-4

  • Online ISBN: 978-3-030-66703-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation